Skip to content
2000
Volume 12, Issue 3
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Melanoma is a common aggressive skin cancer. Its numerous genetic mutations have become rich targets for systemic therapy with chemotherapy or immunotherapy. Surgery is the best initial treatment. Completion nodal dissection for sentinel node positive patients decrease regional occurrence but no survival benefit was found in a few studies. Radiotherapy (RT) is used as primary, adjuvant and palliative treatment. Specific scenarios with unknown primary, head and neck melanomas, and distant metastases are discussed. Systemic therapy includes molecular therapy based on diver mutation or immunotherapy. Treatment guidelines should be utilized by the multidisciplinary team to aid treatment decision making. Future improvement in outcome can only be achieved by enrollment of patient into clinical trials and therefore should be encouraged. Future research will be along the line of immunotherapy, target therapy, hyperthermia, nanoparticles, neutron, and radioisotope treatments.

Loading

Article metrics loading...

/content/journals/cctr/10.2174/1573394713666170113115759
2016-09-01
2025-12-16
Loading full text...

Full text loading...

/content/journals/cctr/10.2174/1573394713666170113115759
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test